Head and Neck Cancers

Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment Selection

November 25, 2022

Ranee Mehra, MD, discusses the link between PD-L1 expression and increased immunotherapy efficacy in head and neck squamous cell carcinoma, and what future treatment options may look like for patients in this space.

5-Year Findings Support Xevinapant Plus Chemotherapy in Locally Advanced Head and Neck Cancer

October 28, 2022

A presentation at the 2022 ESMO Congress found that xevinapant plus chemoradiotherapy decreased the risk of death by twice that of placebo for patients with unresectable, locally advanced head and neck squamous cell carcinoma.